Highlights and Quick Summary
- Other financial activities for the quarter ending June 30, 2023 was $1.69 Million (a 553.88% increase compared to previous quarter)
- Year-over-year quarterly Other financial activities decreased by -103.82%
- Annual Other financial activities for 2022 was $2.88 Million (a 24.08% increase from previous year)
- Annual Other financial activities for 2021 was $2.32 Million (a -122.27% decrease from previous year)
- Annual Other financial activities for 2020 was $-10.4 Million (a -571.75% decrease from previous year)
- Twelve month Other financial activities ending June 30, 2023 was $-41.5 Million (a -1871.14% decrease compared to previous quarter)
- Twelve month trailing Other financial activities decreased by -1520.55% year-over-year
Trailing Other financial activities for the last four month:
| 30 Jun '23 | 31 Mar '23 | 31 Dec '22 | 30 Sep '22 |
|---|---|---|---|
| $-41.5 Million | $2.34 Million | $2.88 Million | $2.92 Million |
Visit stockrow.com/DRRX
for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow
statement with 10 years of data, and state-of-the-art screener.
Historical Other financial activities of DURECT Corporation
Most recent Other financial activitiesof DRRX including historical data for past 10 years.Interactive Chart of Other financial activities of DURECT Corporation
DURECT Corporation Other financial activities for the past 10 Years (both Annual and Quarterly)
(All values are in $ million)
| Year | Q1 | Q2 | Q3 | Q4 | Fiscal Year |
|---|---|---|---|---|---|
| 2023 | $1.69 | $0.26 | – | – | – |
| 2022 | $0.68 | $-44.11 | $45.51 | $0.79 | $2.88 |
| 2021 | $0.73 | $0.76 | $0.06 | $0.77 | $2.32 |
| 2020 | $-12.07 | $0.58 | $0.5 | $0.59 | $-10.4 |
| 2019 | – | – | – | $0.08 | $2.21 |
| 2018 | – | $-0.91 | $-0.11 | $-0.11 | $2.51 |
| 2017 | – | – | – | – | $4.39 |
| 2016 | – | – | $0.0 | $-0.17 | $-0.17 |
| 2015 | $0.0 | $-0.24 | – | – | $-0.24 |
Business Profile of DURECT Corporation
Sector: Healthcare
Industry: Drug Manufacturers Specialty & Generic